Brokerages Expect Spark Therapeutics Inc (ONCE) Will Post Earnings of -$1.04 Per Share

Brokerages predict that Spark Therapeutics Inc (NASDAQ:ONCE) will report earnings of ($1.04) per share for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Spark Therapeutics’ earnings. The highest EPS estimate is ($0.39) and the lowest is ($2.44). Spark Therapeutics reported earnings of ($1.90) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 45.3%. The business is scheduled to issue its next earnings report on Tuesday, November 6th.

According to Zacks, analysts expect that Spark Therapeutics will report full-year earnings of ($1.44) per share for the current fiscal year, with EPS estimates ranging from ($3.81) to $0.34. For the next year, analysts expect that the firm will post earnings of ($3.71) per share, with EPS estimates ranging from ($5.35) to ($1.69). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Spark Therapeutics.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.34). The company had revenue of $25.19 million during the quarter, compared to analysts’ expectations of $29.44 million. Spark Therapeutics had a negative net margin of 185.46% and a negative return on equity of 17.33%.

ONCE has been the subject of several recent research reports. Cantor Fitzgerald set a $103.00 price target on Spark Therapeutics and gave the company a “buy” rating in a research report on Monday, October 1st. Raymond James reiterated a “buy” rating on shares of Spark Therapeutics in a research report on Friday, September 21st. Credit Suisse Group lifted their price target on Spark Therapeutics from $75.00 to $98.00 and gave the company an “outperform” rating in a research report on Monday, July 9th. Guggenheim initiated coverage on Spark Therapeutics in a research report on Tuesday, October 9th. They issued a “buy” rating and a $70.00 price target for the company. Finally, ValuEngine cut Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 4th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $70.10.

Large investors have recently bought and sold shares of the stock. FMR LLC lifted its stake in Spark Therapeutics by 2.6% during the second quarter. FMR LLC now owns 5,536,564 shares of the biotechnology company’s stock worth $458,206,000 after purchasing an additional 142,428 shares during the last quarter. BlackRock Inc. lifted its stake in Spark Therapeutics by 8.7% during the second quarter. BlackRock Inc. now owns 2,869,232 shares of the biotechnology company’s stock worth $237,459,000 after purchasing an additional 229,786 shares during the last quarter. Federated Investors Inc. PA lifted its stake in Spark Therapeutics by 1.8% during the second quarter. Federated Investors Inc. PA now owns 1,524,102 shares of the biotechnology company’s stock worth $126,135,000 after purchasing an additional 26,314 shares during the last quarter. Partner Fund Management L.P. lifted its stake in Spark Therapeutics by 37.5% during the second quarter. Partner Fund Management L.P. now owns 876,779 shares of the biotechnology company’s stock worth $72,562,000 after purchasing an additional 239,143 shares during the last quarter. Finally, Morgan Stanley lifted its stake in Spark Therapeutics by 18.7% during the second quarter. Morgan Stanley now owns 462,121 shares of the biotechnology company’s stock worth $38,244,000 after purchasing an additional 72,744 shares during the last quarter.

Shares of NASDAQ ONCE traded down $2.10 during mid-day trading on Friday, hitting $47.77. The company had a trading volume of 21,049 shares, compared to its average volume of 549,272. The stock has a market cap of $1.91 billion, a PE ratio of -6.28 and a beta of 2.24. Spark Therapeutics has a 1 year low of $41.06 and a 1 year high of $96.59.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Read More: Why is the ex-dividend date different from the record date?

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply